We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Equity
P2P
NextCrowd
Login
Sign Up

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

BLOK

Status: Active

Jun 4th 2018 - Jul 11th 2018

Capital at risk

By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
read more read less
Crowdcube Health and Fitness EIS
Visit Pitch on Crowdcube More about Crowdcube

BLOK Rating Review

Pitch rating powered by CROWDRATING™

Pitch Rated

60%

overall

Management

62%

Product

67%

Investment

51%

Log in to view amount pledged

    Log in to view target

    £9,500,000
    pre-money valuation

    7.32%
    equity available

    571
    investors

    £1,562
    pledge per investor

    09823895
    company number

    Active
    company status

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Officers

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own     50-64%
    Room for improvement     65-79%
    Worth considering     80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

See full risk warning
Click here for more information on our ratings
Login to view the full report

Management 62%

Skills 55%

Visit Pitch on Crowdcube
More about Crowdcube

0 comments

Log in to comment

Funding progress

Log in to view funding progress.

More from Health and Fitness

Optimise BP Envestors Health and Fitness EIS
Optimise BP
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PulmoBioMed Envestors Health and Fitness EIS
PulmoBioMed
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio Limited Envestors Health and Fitness EIS
Carocell Bio Limited
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld

Log in to view amount pledged

    Log in to view target

    £9,500,000
    pre-money valuation

    7.32%
    equity available

    571
    investors

    £1,562
    pledge per investor

    09823895
    company number

    Active
    company status

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Officers
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph

Risk Warning - Summary

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.

Take 2 minutes to learn more.

Investing in equity and debt crowdfunding involves high risks, which may include long-term investment horizons, illiquidity, lack of income, defaulted loans and potential dilution. Any investor needs to be in the position to afford a total loss of capital invested. Investments that are made via Peer to Peer platforms should not be considered deposits like a bank. Your capital is at risk and is not covered by the Financial Service Compensation Scheme (FSCS).

NextFin is targeted at members who have the knowledge and experience to understand these risks and make their own investment decisions. You will NOT invest through NextFin but through the relevant crowdfunding website which also has signed off the content as a Financial Promotion on its own website. NextFin is not the originator of the financial promotions that appear on its site. However we do to the best of our ability carry out limited compliance checks on the originator and the company seeking funding to seek to ensure they are conforming to FCA regulations and anti-money laundering equity/requirements as appropriate. Business Agent Limited, trading as NextFin, takes no responsibility for this information or for any recommendations or opinions made by the companies or its users.

The pitch rating report prepared by CrowdRating and published on NextFin.co.uk does not constitute a personal recommendation, offer or solicitation to buy or sell investments. The pitch rating report should be used as part of your own research to assess whether or not you should make an investment, but only as a single factor and not as a definitive source. If you require advice based on your personal circumstances or are in any doubt about investing, you should obtain advice from an appropriately qualified independent professional. Pitch rating reports are based on publicly available information, including information provided by the investment issuer. CrowdRating assesses that third party information without verifying its accuracy and does not make any representation or warranty as to the accuracy of the information on which it bases its assessments. CrowdRating’s responsibility for their contents is set out in the CrowdRating Terms and Conditions. Business Agent has not prepared or reviewed the contents of the pitch rating reports and is not responsible to you for their contents. Nothing in this Summary shall limit or exclude any liability CrowdRating owes to you under the UK regulatory system. The information and opinions are provided as at the date of the report and are subject to change without notice.

Capital invested in crowdfunding projects is at risk and you may lose some or all of your investment and/or find it difficult to sell. If the investment issuer defaults on its obligations to you, you will not be entitled to compensation from the Financial Services Compensation Scheme. You should only invest in illiquid securities as part of a diversified investment portfolio. Neither CrowdRating nor Business Agent offers personal recommendations on whether investments are suitable for you in light of your investment objectives and financial circumstances.

Click here for our full risk warning.

Company
Learn
Tools
Professional Services
Legal

Legal Notice

The logos and content of each pitch belong to their respective owner. nextfin.uk lists the content for the purpose of review and critique.

The Nextfin website is operated by Business Agent Limited. Business Agent Limited is registered in England & Wales (No: 08819159)

Business Agent Limited is authorised and regulated by the Financial Conduct Authority (FRN: 669880)

Pitch Ratings Reports are provided by Wheatfromchaff Limited trading as CrowdRating and is registered in England & Wales (No: 09328942)

Wheatfromchaff Limited is authorised and regulated by the Financial Conduct Authority (FRN: 751017)

Address: The Townhouse, 114-116 Fore Street, Hertford, Hertfordshire, SG14 1AJ - Tel: 0203 962 0821

© 2024 nextfin.uk, all rights reserved